Research has shown that adding trastuzumab to the chemotherapy regimen results in a reduction of cancer recurrence rates and breast cancer-related mortality by a third [12]. Most women with HER2-positive breast cancer will receive one or more chemotherapy drugs plus trastuzumab, the anti-HER2 antibody. This evidence concerns the gene ERBB2 and cancer.